Management ChangeJul 13, 2026, 07:01 AM
EyePoint Appoints Tarek S. Hassan as Chief Strategic Science Officer
AI Summary
EyePoint, Inc. announced the appointment of Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Officer. Dr. Hassan, a globally recognized retina specialist with over 35 years of experience, will join the executive leadership team and provide strategic guidance for the company's pipeline, including DURAVYU™. His appointment comes at a pivotal time as topline data for DURAVYU's Phase 3 wet AMD trials are expected soon. In connection with his hiring, Dr. Hassan received an inducement grant of 100,000 stock options.
Key Highlights
- EyePoint appointed Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Officer.
- Dr. Hassan will report to CEO Jay S. Duker and join the executive leadership team.
- He brings over 35 years of experience as a globally recognized retina specialist and key opinion leader.
- Dr. Hassan previously served as Past President of the American Society of Retina Specialists (ASRS).
- He was granted 100,000 stock options as an inducement award, vesting over four years.
- Dr. Hassan will provide strategic guidance for EyePoint's pipeline, including DURAVYU™.
Price Impact
More from EYPT